The FDA reviewed labeling definitions and transcatheter valve replacement technology, noting potential benefits from Trump-era tariffs for Abbott and Edwards Lifesciences.
1 report, 1 independent
Updated Jul 9
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA reviewed labeling definitions and transcatheter valve replacement technology, noting potential benefits from Trump-era tariffs for Abbott and Edwards Lifesciences.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
Abbott Laboratories
American global health care and medical device products company
-
Edwards Lifesciences
American medical technology company
Related events
- Future sales of a product are contingent upon obtaining the necessary FDA registration and labeling, while the state simultaneously announces actions to remove regulatory barriers.
- FDA approved expanded use of Sapien 3 valves, while Edwards conducts Progress trials and seeks expanded Medicare coverage for TAVR.
- FDA approval is the goal for product candidates from Daré Bioscience, Inc.
- Congress considered proposals to strengthen FDA authority regarding medical device regulation and minimum standards.
- The FDA authorized drug use in New Mexico and Texas, while the Trump administration faced criticism over trade decisions.
Coverage
Newest first; wire copies grouped- Insider MonkeyOppenheimer Reiterates ‘Outperform’ Rating on Abbott Laboratories (ABT) Abbott Laboratories (NYSE:ABT) is one of the top 10 defensive stocks to consider in a volatile market. On July 3, analysts at O